FDA Fundamental Analysis - FIDIA SPA

Fundamental Rating

Taking everything into account, FDA scores 1 out of 10 in our fundamental rating. FDA was compared to 108 industry peers in the Machinery industry. FDA may be in some trouble as it scores bad on both profitability and health. FDA does not seem to be growing, but still is valued expensively.

Quickly go to:

1. Profitability

1.1 Basic Checks

FDA had negative earnings in the past year.

FDA had a positive operating cash flow in the past year.

FDA had negative earnings in 4 of the past 5 years.

The reported operating cash flow has been mixed in the past 5 years: FDA reported negative operating cash flow in multiple years.

1.2 Ratios

FDA has a Return On Assets of -8.49%. This is amonst the worse of the industry: FDA underperforms 81.48% of its industry peers.

FDA's Return On Equity of -53.14% is on the low side compared to the rest of the industry. FDA is outperformed by 83.33% of its industry peers.

		Industry Rank	Sector Rank
ROA	-8.49%
ROE	-53.14%
ROIC	N/A

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

1.3 Margins

The Gross Margin of FDA (69.64%) is better than 94.44% of its industry peers.

FDA's Gross Margin has improved in the last couple of years.

The Profit Margin and Operating Margin are not available for FDA so they could not be analyzed.

		Industry Rank	Sector Rank
OM	N/A
PM (TTM)	N/A
GM	69.64%

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y4.42%

GM growth 5Y4.76%

More info and screens

ROA

ROE

ROIC

Operating and Profit Margin

Show most profitable peers

2. Health

2.1 Basic Checks

FDA does not have a ROIC to compare to the WACC, probably because it is not profitable.

There is no outstanding debt for FDA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.

2.2 Solvency

FDA has an Altman-Z score of 0.11. This is a bad value and indicates that FDA is not financially healthy and even has some risk of bankruptcy.

Looking at the Altman-Z score, with a value of 0.11, FDA is doing worse than 76.85% of the companies in the same industry.

FDA has a debt to FCF ratio of 6.13. This is a slightly negative value and a sign of low solvency as FDA would need 6.13 years to pay back of all of its debts.

FDA's Debt to FCF ratio of 6.13 is in line compared to the rest of the industry. FDA outperforms 52.78% of its industry peers.

A Debt/Equity ratio of 1.41 is on the high side and indicates that FDA has dependencies on debt financing.

FDA has a Debt to Equity ratio of 1.41. This is amonst the worse of the industry: FDA underperforms 80.56% of its industry peers.

		Industry Rank	Sector Rank
Debt/Equity	1.41
Debt/FCF	6.13
Altman-Z	0.11

ROIC/WACCN/A

WACC8.08%

2.3 Liquidity

FDA has a Current Ratio of 1.06. This is a normal value and indicates that FDA is financially healthy and should not expect problems in meeting its short term obligations.

FDA has a worse Current ratio (1.06) than 76.85% of its industry peers.

A Quick Ratio of 0.46 indicates that FDA may have some problems paying its short term obligations.

Looking at the Quick ratio, with a value of 0.46, FDA is doing worse than 90.74% of the companies in the same industry.

		Industry Rank	Sector Rank
Current Ratio	1.06
Quick Ratio	0.46

More info and screens

WACC

Debt/Equity

How to determine the health of a company

Altman-Z score

Show peers with great health

3. Growth

3.1 Past

FDA shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 70.56%, which is quite impressive.

Looking at the last year, FDA shows a very negative growth in Revenue. The Revenue has decreased by -27.40% in the last year.

The Revenue for FDA have been decreasing by -17.51% on average. This is quite bad

EPS 1Y (TTM)70.56%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%99.95%

Revenue 1Y (TTM)-27.4%

Revenue growth 3Y-9.81%

Revenue growth 5Y-17.51%

Sales Q2Q%38.18%

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

Find the best growth stocks

Show best growing peers

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for FDA. In the last year negative earnings were reported.

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A

4.2 Price Multiples

FDA's Price/Free Cash Flow ratio is rather cheap when compared to the industry. FDA is cheaper than 97.22% of the companies in the same industry.

		Industry Rank	Sector Rank
P/FCF	2.68
EV/EBITDA	N/A

4.3 Compensation for Growth

PEG (NY)N/A

PEG (5Y)N/A

EPS Next 2YN/A

EPS Next 3YN/A

More info and screens

Show best valued peers

5. Dividend

5.1 Amount

FDA does not give a dividend.

		Industry Rank	Sector Rank
Dividend Yield	N/A

More info and screens

Find the best dividend stocks

Show peers with best dividend

FIDIA SPA

BIT:FDA (11/25/2025, 7:00:00 PM)

0.1961

-0.01 (-3.87%)

Chartmill FA Rating

GICS SectorIndustrials

GICS IndustryGroupCapital Goods

GICS IndustryMachinery

Earnings (Last)N/A N/A

Earnings (Next)N/A N/A

Inst Owners0%

Inst Owner ChangeN/A

Ins Owners3.45%

Ins Owner ChangeN/A

Market Cap2.99M

Revenue(TTM)21.08M

Net Income(TTM)-2.19M

Analysts45.71

Price TargetN/A

Short Float %N/A

Short RatioN/A

Dividend

		Industry Rank	Sector Rank
Dividend Yield	N/A

Yearly DividendN/A

Dividend Growth(5Y)N/A

DP0%

Div Incr Years0

Div Non Decr Years0

Ex-DateN/A

Surprises & Revisions

EPS beat(2)N/A

Avg EPS beat(2)N/A

Min EPS beat(2)N/A

Max EPS beat(2)N/A

EPS beat(4)N/A

Avg EPS beat(4)N/A

Min EPS beat(4)N/A

Max EPS beat(4)N/A

EPS beat(8)N/A

Avg EPS beat(8)N/A

EPS beat(12)N/A

Avg EPS beat(12)N/A

EPS beat(16)N/A

Avg EPS beat(16)N/A

Revenue beat(2)N/A

Avg Revenue beat(2)N/A

Min Revenue beat(2)N/A

Max Revenue beat(2)N/A

Revenue beat(4)N/A

Avg Revenue beat(4)N/A

Min Revenue beat(4)N/A

Max Revenue beat(4)N/A

Revenue beat(8)N/A

Avg Revenue beat(8)N/A

Revenue beat(12)N/A

Avg Revenue beat(12)N/A

Revenue beat(16)N/A

Avg Revenue beat(16)N/A

PT rev (1m)0%

PT rev (3m)0%

EPS NQ rev (1m)N/A

EPS NQ rev (3m)N/A

EPS NY rev (1m)N/A

EPS NY rev (3m)N/A

Revenue NQ rev (1m)N/A

Revenue NQ rev (3m)N/A

Revenue NY rev (1m)N/A

Revenue NY rev (3m)N/A

Valuation

		Industry Rank	Sector Rank
PE	N/A
Fwd PE	N/A
P/S	0.14
P/FCF	2.68
P/OCF	2.34
P/B	0.72
P/tB	0.83
EV/EBITDA	N/A

EPS(TTM)-6.13

EYN/A

EPS(NY)N/A

Fwd EYN/A

FCF(TTM)0.07

FCFY37.3%

OCF(TTM)0.08

OCFY42.72%

SpS1.38

BVpS0.27

TBVpS0.24

PEG (NY)N/A

PEG (5Y)N/A

Graham NumberN/A

Profitability

		Industry Rank	Sector Rank
ROA	-8.49%
ROE	-53.14%
ROCE	N/A
ROIC	N/A
ROICexc	N/A
ROICexgc	N/A
OM	N/A
PM (TTM)	N/A
GM	69.64%
FCFM	5.28%

ROA(3y)N/A

ROA(5y)N/A

ROE(3y)N/A

ROE(5y)N/A

ROIC(3y)N/A

ROIC(5y)N/A

ROICexc(3y)N/A

ROICexc(5y)N/A

ROICexgc(3y)N/A

ROICexgc(5y)N/A

ROCE(3y)N/A

ROCE(5y)N/A

ROICexgc growth 3YN/A

ROICexgc growth 5YN/A

ROICexc growth 3YN/A

ROICexc growth 5YN/A

OM growth 3YN/A

OM growth 5YN/A

PM growth 3YN/A

PM growth 5YN/A

GM growth 3Y4.42%

GM growth 5Y4.76%

F-Score5

Asset Turnover0.82

Health

		Industry Rank	Sector Rank
Debt/Equity	1.41
Debt/FCF	6.13
Debt/EBITDA	N/A
Cap/Depr	12.72%
Cap/Sales	0.77%
Interest Coverage	N/A
Cash Conversion	N/A
Profit Quality	N/A
Current Ratio	1.06
Quick Ratio	0.46
Altman-Z	0.11

F-Score5

WACC8.08%

ROIC/WACCN/A

Cap/Depr(3y)19.7%

Cap/Depr(5y)16.39%

Cap/Sales(3y)1.17%

Cap/Sales(5y)1.24%

Profit Quality(3y)N/A

Profit Quality(5y)N/A

High Growth Momentum

Growth

EPS 1Y (TTM)70.56%

EPS 3YN/A

EPS 5YN/A

EPS Q2Q%99.95%

EPS Next YN/A

EPS Next 2YN/A

EPS Next 3YN/A

EPS Next 5YN/A

Revenue 1Y (TTM)-27.4%

Revenue growth 3Y-9.81%

Revenue growth 5Y-17.51%

Sales Q2Q%38.18%

Revenue Next YearN/A

Revenue Next 2YN/A

Revenue Next 3YN/A

Revenue Next 5YN/A

EBIT growth 1Y-112.29%

EBIT growth 3YN/A

EBIT growth 5YN/A

EBIT Next YearN/A

EBIT Next 3YN/A

EBIT Next 5YN/A

FCF growth 1Y-50.51%

FCF growth 3YN/A

FCF growth 5YN/A

OCF growth 1Y-48.73%

OCF growth 3YN/A

OCF growth 5YN/A

FIDIA SPA / FDA.MI FAQ

What is the ChartMill fundamental rating of FIDIA SPA (FDA.MI) stock?

ChartMill assigns a fundamental rating of 1 / 10 to FDA.MI.

Can you provide the valuation status for FIDIA SPA?

ChartMill assigns a valuation rating of 2 / 10 to FIDIA SPA (FDA.MI). This can be considered as Overvalued.

How profitable is FIDIA SPA (FDA.MI) stock?

FIDIA SPA (FDA.MI) has a profitability rating of 2 / 10.

Can you provide the financial health for FDA stock?

The financial health rating of FIDIA SPA (FDA.MI) is 1 / 10.

FIDIA SPA (FDA.MI) Stock Fundamental Analysis

1. Profitability

1.1 Basic Checks

1.2 Ratios

1.3 Margins

More info and screens

2. Health

2.1 Basic Checks

2.2 Solvency

2.3 Liquidity

More info and screens

3. Growth

3.1 Past

3.2 Future

3.3 Evolution

More info and screens

4. Valuation

4.1 Price/Earnings Ratio

4.2 Price Multiples

4.3 Compensation for Growth

More info and screens

5. Dividend

5.1 Amount

More info and screens

FIDIA SPA / FDA.MI FAQ

What is the ChartMill fundamental rating of FIDIA SPA (FDA.MI) stock?

Can you provide the valuation status for FIDIA SPA?

How profitable is FIDIA SPA (FDA.MI) stock?

Can you provide the financial health for FDA stock?